Centers of Disease Control and Prevention: CDC's Advisory Committee Recommends Human Papillomavirus Virus Vaccination. [http://www.cdc.gov/od/oc/media/pressrel/r060629.htm]
American Cancer Society: Detailed Guide: Cervical Cancer-What Are the Key Statistics About Cervical Cancer?. [http://www.cancer.org/docroot/CRI/content/CRI_2_4_1X_What_are_the_key_statistics_for_cervical_cancer_8.asp]
Schiffman M, Solomon D: Findings to date from the ASCUS-LSIL Triage Study (ALTS). Arch Pathol Lab Med. 2003, 127: 946-949.
Wright TC, Schiffman M, Solomon D, Cox JT, Garcia F, Goldie S, Hatch K, Noller KL, Roach N, Runowicz C, Saslow D: Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol. 2004, 103: 304-309.
ACOG Practice Bulletin No. 61: Human Papillomavirus. Obstet Gynecol. 2005, 105: 905-918.
Massad LS, Schneider MF, Watts DH, Strickler HD, Melnick S, Palefsky J, Anastos K, Levine AM, Minkoff H: HPV testing for triage of HIV-infected women with papanicolaou smears read as atypical squamous cells of uncertain significance. J Womens Health (Larchmt). 2004, 13: 147-53.
Lonky NM, Felix JC, Naidu YM, Wolde-Tsadik G: Triage of atypical squamous cells of undetermined significance with hybrid capture II: colposcopy and histologic human papillomavirus correlation. Obstet Gynecol. 2003, 101: 481-489. 10.1016/S0029-7844(02)02715-1.
Boardman LA, Weitzen S, Stanko C: Atypical squamous cells of undetermined significance, human papillomavirus, and cervical intraepithelial neoplasia 2 or 3 in adolescents: ASC-US, age, and high-grade cervical neoplasia. J Low Genit Tract Dis. 2006, 10: 140-145. 10.1097/00128360-200607000-00004.
Ronco G, Cuzick J, Segnan N, Brezzi S, Carozzi F, Folicaldi S, Dalla Palma P, Del Mistro A, Gillio-Tos A, Giubilato P, Naldoni C, Polla E, Iossa A, Zorzi M, Confortini M, Giorgi-Rossi P, NTCC working group: HPV triage for low grade (L-SIL) cytology is appropriate for women over 35 in mass cervical cancer screening using liquid based cytology. Eur J Cancer. 2007, 43: 476-480. 10.1016/j.ejca.2006.11.013.
Stout NK, Goldhaber-Fiebert JD, Ortendahl JD, Goldie SJ: Trade-offs in cervical cancer prevention: balancing benefits and risks. Arch Intern Med. 2008, 168: 1881-1889. 10.1001/archinte.168.17.1881.
Moriarty AT, Schwartz MR, Eversole G, Means M, Clayton A, Souers R, Fatheree L, Tench WD, Henry M, Wilbur DC: Human papillomavirus testing and reporting rates: practices of participants in the College of American Pathologists Interlaboratory Comparison Program in Gynecologic Cytology in 2006. Arch Pathol Lab Med. 2008, 132: 1290-1294.
Seabrook JM, Hubbard RA: Achieving quality reproducible results and maintaining compliance in molecular diagnostic testing of human papillomavirus. Arch Pathol Lab Med. 2003, 127: 978-983.
Fischer AH: College of American Pathologists – Practice patterns in HPV testing. 2008, CAP Today. August issue
Stoler MH, Castle PE, Solomon D, Schiffman M: The Expanded Use of HPV Testing in Gynecologic Practice per ASCCP-Guided Management Requires the Use of Well-Validated Assays. Am J Clin Pathol. 2007, 127: 1-3. 10.1309/RNF3C01JKADQCLKP.
Galgano MT, Castle PE, Stoler MH, Solomon D, Schiffman M: Can HPV-16 genotyping provide a benchmark for cervical biopsy specimen interpretation?. Am J Clin Pathol. 2008, 130: 65-70. 10.1309/A8MFC18TWANC8QFH.
Klug SJ, Molijn A, Schopp B, Holz B, Iftner A, Quint W, JF Snijders P, Petry KU, Krüger Kjaer S, Munk C, Iftner T: Comparison of the performance of different HPV genotyping methods for detecting genital HPV types. J Med Virol. 2008, 80: 1264-1274. 10.1002/jmv.21191.
van Doorn LJ, Quint W, Kleter B, Molijn A, Colau B, Martin MT, Kravang-In , Torrez-Martinez N, Peyton CL, Wheeler CM: Genotyping of human papillomavirus in liquid cytology cervical specimens by the PGMY line blot assay and the SPF(10) line probe assay. J Clin Microbiol. 2002, 40: 979-983. 10.1128/JCM.40.3.979-983.2002.
Gutman S: FDA Reclassification Order, Docket No. 2007P-0210. 2007, [http://www.hifidna.com/News%20&%20Events%20files/Gutman+FDA.pdf]
de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H: Classification of papillomaviruses. Virology. 2004, 324: 17-27. 10.1016/j.virol.2004.03.033.
Feoli-Fonseca JC, Oligny LL, Filion M, Brochu P, Simard P, Russo PA, Yotov WV: A two-tier polymerase chain reaction direct sequencing method for detecting and typing human papillomaviruses in pathological specimens. Diagn Mol Pathol. 1998, 7: 317-323. 10.1097/00019606-199812000-00005.
Vernon SD, Unger ER, Williams D: Comparison of human papillomavirus detection and typing by cycle sequencing, line blotting, and hybrid capture. J Clin Microbiol. 2000, 38: 651-655.
Johnson T, Bryder K, Corbet S, Fomsgaard A: Routine genotyping of human papillomavirus samples in Denmark. APMIS. 2003, 111: 398-404. 10.1034/j.1600-0463.2003.t01-1-1110204.x.
Speich N, Schmitt C, Bollmann R, Bollmann M: Human papillomavirus (HPV) study of 2916 cytological samples by PCR and DNA sequencing: genotype spectrum of patients from the west German area. J Med Microbiol. 2004, 53: 125-128. 10.1099/jmm.0.05447-0.
Kosel S, Burggraf S, Mommsen J, Engelhardt W, Olgemoller B: Type-specific detection of human papillomaviruses in a routine laboratory setting – improved sensitivity and specificity of PCR and sequence analysis compared to direct hybridisation. Clin Chem Lab Med. 2003, 41: 787-791. 10.1515/CCLM.2003.119.
Asato T, Maehama T, Nagai Y, Kanazawa K, Uezato H, Kariya K: A large case-control study of cervical cancer risk associated with human papillomavirus infection in Japan, by nucleotide sequencing-based genotyping. J Infect Dis. 2004, 189: 1829-1832. 10.1086/382896.
Lee SH, Vigliotti VS, Vigliotti JS, Pappu S: Routine human papillomavirus genotyping by DNA sequencing in community hospital laboratories. Infect Agent Cancer. 2007, 2: 11-10.1186/1750-9378-2-11. doi:10.1186/1750-9378-2-11
Lee SH, Vigliotti VS, Pappu S: DNA Sequencing Validation of Chlamydia trachomatis and Neisseria gonorrhoeae Nucleic Acid Tests. Am J Clin Pathol. 2008, 129: 852-859. 10.1309/Y2202RVCGRWW1RWB.
Lee SH, Vigliotti VS, Vigliotti JS, Pappu S: Molecular tests for human papillomavirus (HPV), Chlamydia trachomatis and Neisseria gonorrhoeae in liquid-based Pap cytology specimen. BMC Women's Health. 2009, 9: 8-10.1186/1472-6874-9-8. doi:10.1186/1472-6874-9-8
Hovey D: State must do more to prevent cervical cancer. [http://www.housegop.ct.gov/%5Cpressrel%5CHoveyD112%5C2007%5C20070116_HoveyD112_01.pdf]
Lee SH, Vigliotti VS, Pappu S: Human papillomavirus infection among women in a representative rural and suburban population of the United States. Int J Gyn Ob. 2009, 105: 210-214. 10.1016/j.ijgo.2009.01.019.
Gharizadeh B, Oggionni M, Zheng B, Akom E, Pourmand N, Ahmadian A, Wallin KL, Nyren P: Type-specific multiple sequencing primers: a novel strategy for reliable and rapid genotyping of human papillomaviruses by pyrosequencing technology. J Mol Diagn. 2005, 7: 198-205.
VRBPAC Background Document: Gardasil™ HPV Quadrivalent Vaccine. VRBPAC Meeting M18. 2006, [http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4222B3.pdf]
Wallin KL, Wiklund F, Angström T, Bergman F, Stendahl U, Wadell G, Hallmans G, Dillner J: Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med. 1999, 341: 1633-1638. 10.1056/NEJM199911253412201.
Kjaer SK, Brule van den AJ, Paull G, Svare EI, Sherman ME, Thomsen BL, Suntum M, Bock JE, Poll PA, Meijers CJ: Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ. 2002, 325: 572-576. 10.1136/bmj.325.7364.572.
Cuschieri KS, Cubie HA, Whitley MW, Gilkison G, Arends MJ, Graham C, McGoogan E: Persistent high risk HPV infection associated with development of cervical neoplasia in a prospective population study. J Clin Pathol. 2005, 58: 946-950. 10.1136/jcp.2004.022863.
Brummer O, Hollwitz B, Bohmer G, Kuhnle H, Petry KU: Human papillomavirus-type persistence patterns predict the clinical outcome of cervical intraepithelial neoplasia. Gynecol Oncol. 2006, 102: 517-522. 10.1016/j.ygyno.2006.01.020.
Lu H, Ouyang W, Huang C: Inflammation, a key event in cancer development. Mol Cancer Res. 2006, 4: 221-233. 10.1158/1541-7786.MCR-05-0261.
Terai M, Burk RD: Complete nucleotide sequence and analysis of a novel human papillomavirus (HPV 84) genome cloned by an overlapping PCR method. Virology. 2001, 279: 109-115. 10.1006/viro.2000.0716.
Schiffman M, Wheeler CM, Dasgupta A, Solomon D, Castle PE, The ALTS Group: A comparison of a prototype PCR assay and hybrid capture 2 for detection of carcinogenic human papillomavirus DNA in women with equivocal or mildly abnormal Papanicolaou smears. Am J. 2005, 124: 722-732.
Menzo S, Ciavattini A, Bagnarelli P, Marinelli K, Sisti S, Clementi M: Molecular epidemiology and pathogenic potential of underdiagnosed human papillomavirus types. BMC Microbiol. 2008, 8: 112-10.1186/1471-2180-8-112. doi:10.1186/1471-2180-8-112
Menzo S, Monachetti A, Trozzi C, Ciavattini A, Carloni G, Varaldo PE, Clementi M: Identification of six putative novel human papillomaviruses (HPV) and characterization of candidate HPV type 87. J Virol. 2001, 75: 11913-11919. 10.1128/JVI.75.23.11913-11919.2001.